NCT00143741View on ClinicalTrials.gov

Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

December 31, 2010

Study Completion Date

July 31, 2011

Conditions
End-Stage Kidney Disease
Interventions
DRUG

Atorvastatin (Lipitor)

20mg every day, taken by mouth. Dose could be increased up to 60mg every day during the course of the trial if tests indicate this is needed.

Trial Locations (1)

60637

The University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT00143741 - Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers | Biotech Hunter | Biotech Hunter